Angiopoietin-like protein as a novel marker for liver fibrosis in chronic hepatitis B patients with normal to minimally raised ALT

Yongqiong Deng¹,²†, Hong Zhao¹†, Jiyuan Zhou¹, Linlin Yan¹, Guiqiang Wang¹,³,⁴* and China HepB-Related Fibrosis Assessment Research Group

Abstract

Background: For hepatitis B patients who do not meet the treatment criteria recommended by guidelines, therapy decisions depend on hepatic histology. Angiopoietin-like protein 2 (Angptl2) is a mediator of chronic inflammation that contributes to extracellular matrix remodeling. The aim of this study was to explore the predictive value of Angptl2 as a novel biomarker of liver histology.

Methods: Hepatitis B patients with normal to minimally raised ALT were recruited. Serum Angptl2 concentrations were detected using commercial ELISA kit. The fibrosis score were assessed according to Ishak criteria. Significant fibrosis was defined as ISHAK score ≥ 3.

Results: Of 460 patients, 223 cases served as training cohort and 237 ones as validation cohort. Serum Angptl2 concentration was significantly associated with fibrosis scores in both training and validation group. Angptl2 combined index (ACI) for assessing significant fibrosis was developed from training cohort, based on Angptl2 and conventional variables. ACI showed areas under receiver-operating characteristic curve (AUC) of 0.835 for predicting significant fibrosis, which was superior to APRI (AUC = 0.776, P = 0.049), FIB-4 (AUC = 0.750, P = 0.010), Hui model (AUC = 0.756, P = 0.028), and had a better trend than Forn’s index (AUC = 0.796, P = 0.083) in training cohort. Finally, validation cohort revealed its robustness and reliability.

Conclusion: Higher Angptl2 level represents as a potential biomarker independently associated with fibrosis stages. Compared with APRI, Hui model, FIB-4, Forn’s index, ACI did better in diagnosing significant fibrosis in hepatitis B patients.

Trial registration: The complete clinical trials protocol is available by request at clinicaltrials.gov (NCT01962155) and chictr.org (ChiCTR-DDT-13003724).

Keywords: Angiopoietin-like protein, Hepatitis B, Liver fibrosis
Background
Approximately 3.61% of the world’s population (248 million individuals) is chronically infected with hepatitis B virus (HBV), and China, India, and Nigeria are the top three countries with the highest population of HBV surface antigen (HBsAg) positive patients [1]. At least 30% of cirrhosis and 50% of hepatocellular carcinoma (HCC) cases are associated with chronic HBV infection [2]. From an epidemiological survey conducted by the Chinese Center for Disease Control and Prevention in 2006, the weighted prevalence of HBsAg, anti-HBs, and hepatitis B core antigen antibody (anti-HBc) in Chinese individuals aged 1 to 59 years was 7.2, 50.1, and 34.1%, respectively [3]. An accurate initial evaluation of liver damage and the correct treatment decision for this population will not only decrease the future incidence of cirrhosis and HCC but also improve the quality of life and the survival rate. The 2015 APASL guidelines recommend immediately antiviral therapy for HBeAg-positive patients with HBV DNA levels ≥20,000 IU/ml or HBeAg-negative patients with HBV DNA levels ≥2000 IU/ml as well as patients with alanine aminotransferase (ALT) levels greater than 2 times the upper limit of normal (ULN); for patients with ALT <2 × ULN and HBV DNA below thresholds, treatment was suggested if moderate to severe inflammation or significant fibrosis (Ishak fibrosis score ≥ 3) [4]. Although liver biopsy was considered as the reference standard for staging inflammation and fibrosis, it was imperfect due to its invasiveness, sampling bias, intra-observer variations, risk of bile leakage, and hemorrhage [5–7]. In the last two decades, a variety of biomarkers and indexes has been developed for non-invasive diagnosis. But few of them were designed for hepatitis B patients with normal to minimally raised aminotransferases, for whom therapy decisions depend on hepatic histology.

Angptl2, a member of the angiopoietin-like protein family, has been recently shown to mediate chronic inflammation and subsequent pathological irreversible tissue remodeling [8]. Angptl2 increases matrix metalloproteinase (MMP) expression and activity through integrin α5β3-mediated activation of P38 mitogen-activated protein kinase (MAPK), thus promoting extracellular matrix (ECM) remodeling [9, 10]. Integrins, which act as functional receptors for Angptl2, are abundantly expressed on macrophages, endothelial cells, and adipocytes [8, 10]. Activated macrophages play a major role in chronic liver disease by synthesizing and releasing a battery of pro-fibrogenic and pro-inflammatory mediators [11]. It reported that angptl2 mRNA was expressed in liver and secreted by hepatocytes [12]. Additionally, higher level of Angptl2 in serum has been found in patients with non-small cell lung cancer, arteriosclerotic occlusion, gastric cancer [13–15], but whether the circulatory concentration of angptl2 increased in liver disease was unknown. In this study, we hypothesized that Angptl2 participates in hepatic fibrogenesis in chronic liver disease and would be as a potential biomarker for diagnosis of liver fibrosis. The information presented herein might help to improve treatment decision making and avoid liver biopsy in patients with hepatitis.

Methods
Patients
Patients aged 18 – 65 years who showed HBsAg positivity for at least 6 months were recruited from 24 centers in Mainland China between October 2013 and May 2016. All patients were treatment naive. Exclusion criteria for this study included concomitant infection with hepatitis C virus (HCV) or human immunodeficiency virus (HIV) and other chronic liver diseases, such as alcoholic liver disease, autoimmune liver disease, heretic liver disease, drug-induced liver disease, and nonalcoholic liver disease. Patients with HCC or decompensate cirrhosis were also excluded. Clinical data, including age, gender, and body mass index (BMI), were recorded at the time of liver biopsy. There were 30 healthy people recruited as control subjects.

Laboratory tests
Serum hematological and biochemical parameters, such as platelet counts (PLT), ALT, aspartate aminotransferase (AST), albumin, gamma-glutamyltransferase (GGT), prothrombin time (PT), Total bilirubin (TBil) and cholesterol, were routinely obtained within 4 weeks of liver biopsy using standard methodologies in local hospitals. In this study, we are using ALT of 40 IU/ml as the upper limit of the normal [4].

Serum HBsAg levels were quantified using the Roche Elecsys® HBsAg II assay (Roche Diagnostics, Penzberg, Germany), and serum HBV-DNA (dynamic range 2.0 × 10^4 – 1.7 × 10^8 IU/ml) was measured with the COBAS AmpliPrep/COBAS TaqMan method as previously described [16]. The qualitative detection of HBeAg and anti-HBe was also performed using relevant Roche Elecsys® assays according to the manufacturer’s instructions.

The serum concentrations of Collagen IV, laminin (LN), hyaluronic acid, procollagen type III N-terminal peptide (PIIINP) were detected as previously described [17].

Non-invasive indexes for fibrosis, such as APRI, FIB-4, AAR, and Forns’ index, were calculated as follows: APRI = [(AST/ULN)/platelet count] × 10^9/L) × 100; FIB-4 = (age × AST)/(platelet count) × 10^9/L × ALT^1/2; Forns’ index = 7.811 – 3.131 × LN(Platelet count) + 0.781 × LN(GGT) + 3.467 × LN(Age) – 0.014 × LN(cholesterol); Hui model : gx = 1.23 + 0.167 × BMI + 1.191 × (ALP/135) + 0.081 × TBi – 0.139 × Albumin – 0.017 × PLT, Hui model = exp . (gx)/(1 + exp . (gx)) [18–21].
Receiver-operating characteristic (ROC) curves were developed by the formula exp.(gx)/(1 + exp.(gx)).

pendent factors and their coefficients, then the model ACI analysis. We calculated a new index gx based on the inde-
w a so u t p u ta tt h el a s ts t e po ft h eb i n a r yl o g i s t i cr e g r e s s i o n
while the regression coefficient of each independent factors
dependent and variables as explanatory variables. Mean-
lysis was conducted with ISHAK fibrosis stage as the
fibrosis, a binary backward stepwise logistic regression ana-
"s correlation coefficient was used
sr a n kt e s w e r e
p
statistically different between training and validation cohort, fibrosis
stages equally distributed in the two sets ($P = 0.835$).

The 30 healthy people aged 18 to 65 years ($\geq 40$ year,
$\geq 13$) were recruited as control subjects, of whom the
normal ALT, AST, ALP, GGT, Albumin, TBil, PT, Hyaluronic and HBV DNA indicated statistically dif-
fiberosis, who had the Angptl2 level of 4.16 ± 1.66 (ng/ml).

Serum Angptl2 concentration
Serum Angptl2 concentrations were determined using the Human ANGPTL2 Assay kit (Immuno-Biological Laboratories Co., Ltd., Japan) according to the manufacturer’s instructions. To ensure that all samples underwent only one freeze-thaw cycle, the blood samples obtained were used to generate small volume aliquots, which were stored at $-80\,^\circ{C}$. All Angptl2 tests were performed within 2 weeks. The samples were retested if the coefficient of variation between the duplicate wells was less than 10% or if the R squared value of the standard curve was less than 0.99. In this study, we detected angptl2 concentration in both patients with hepatitis B and 30 healthy people as control.

Hepatic histological assessment
Ultrasoundographic-guided liver biopsies were routinely processed at each institute according to a standardized protocol after receiving the patient’s written informed consent. Specimens were fixed, paraffin-embedded, and stained with hematoxylin-eosin and Mason’s trichrome. A minimum of 2.0 cm of liver tissue with at least 11 portal tracts was required for diagnosis. Pathological interpreta-
tions were conducted in the Department of Pathology at the You An Hospital affiliated with Capital Medical Uni-
versity. Each section was blindly and independently assessed by 2 pathologists. When discrepancies occurred, the samples were reviewed by experienced pathologists who were also responsible for reassessment in 10% of randomly selected samples. The strength of concordance was defined by the kappa value. To minimize inter- and intra-
observer discrepancies, pre-reading was conducted, and a kappa value of 0.81 was required. The histological fibrosis stage were assessed according to Ishak criteria [22].

Statistical analysis
Statistical analyses were performed using SPSS 17.0. Quan-
titative variables were expressed as the mean ± standard de-
Vation (SD) unless otherwise specified. Categorical variables were compared using Chi-squared tests, and con-
tinuous variables were compared using the Kruskal-Wallis and Mann-Whitney U-tests. Spearman’s rank tests were used to study associations between variables and histo-
logical scores. Spearman’s correlation coefficient was used as necessary. To determine the independent factors of liver fibrosis, a binary backward stepwise logistic regression ana-
lysis was conducted with ISHAK fibrosis stage as the dependent and variables as explanatory variables. Mean-
while the regression coefficient of each independent factors
was output at the last step of the binary logistic regression analysis. We calculated a new index gx based on the inde-
pendent factors and their coefficients, then the model ACI was developed by the formula exp.(gx)/(1 + exp.(gx)). Receiver-operating characteristic (ROC) curves were created for the assessment of variables for staging fibrosis. The performance of variables for predicting the severity of liver damage, expressed as AUC, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), was calculated. Comparison of ROC curves was performed by MedCalc. All $p$ values reported are two sided, and $p < 0.05$ was considered statistically significant.

Results
Clinical characteristics of study population
Although there were 685 hepatitis B patients collected, only 460 patients with ALT $<2\times$ ULN and qualified biopsy were analyzed in this study. According to the order into the project, 223 cases served as training cohort and 237 ones as validation cohort. Among total patients with normal to minimally raised ALT, one hundred and sixty nine ones showed significant/severe fibrosis ($F \geq 3$, 36.8%) (Table 1). In patients with low normal ($<0.5 \times$ ULN,
$n = 51$), high normal(between 0.5 and 1 × ULN, $n = 145$) and minimally raised ALT (between ULN and 2 × ULN, $n = 264$), Ishak fibrosis score $\geq 3$ diagnosed in 13 (25.5%), 55 (37.9%), 100 (38.9%) cases respectively, the data was not shown. Although serum level of AST, Albumin, TBil, PT, Hyaluronic and HBV DNA indicated statistically dif-
erent between training and validation cohort, fibrosis
stages equally distributed in the two sets ($P = 0.835$).

Serum Angptl2 concentration independently associated with significant fibrosis in training group
In 30 healthy people, we detected the Angptl2 concentra-
tion of 3.92 ± 1.53 (ng/ml) in serum, which was not different from that in patients with no/moderate fibrosis. However, serum Angptl2 concentration was closely associ-
ated with Ishak fibrosis scores for patients in training group, higher the fibrosis stages resulted in higher serum Angptl2 concentrations ($p < 0.001$) (Fig. 1). In patients with normal ALT ($n = 88$), the higher Angptl2 concentration of 6.05 ± 3.94 (ng/ml) was found in 27 (30.7%) patients with significant fibrosis, compared to those with no/moderate fi-
brosis, who had the Angptl2 level of 4.16 ± 1.66 (ng/ml).

Apart from the higher serum concentrations of Angptl2 in the patients with significant fibrosis, higher levels of Age, AST, ALP, GGT, albumin, PT, hyaluronic, LN, PIIINP, and Collagen IV, as well as lower HBsAg titers and PLT were also found when compared to the other ones with nil/mod-
erate fibrosis. Finally, BMI, age, gender which has been re-
ported to be associated with liver fibrosis and other
### Table 1: Baseline Characteristics: Comparison Between the Training and the Validation cohort

| Parameter                        | Training cohort (n = 223) | Validation cohort (n = 237) | Total (n = 460) | P value |
|----------------------------------|--------------------------|-----------------------------|-----------------|---------|
| Age (≥40 year, %)                | 98 (43.9%)               | 107 (45.1%)                 | 205 (44.6%)     | 0.851   |
| Gender (Male, %)                 | 170 (76.2%)              | 175 (73.8%)                 | 345 (75.0%)     | 0.591   |
| BMI (≥24 kg/m², %)               | 82 (36.8%)               | 84 (35.4%)                  | 166 (36.1%)     | 0.772   |
| Platelet count (× 10^9/L)        | 173.57 ± 56.23           | 172.42 ± 60.38              | 172.33 ± 59.08  | 0.526   |
| ALT (U/L)                        | 44.28 ± 17.13            | 41.93 ± 17.02               | 43.07 ± 17.10   | 0.163   |
| AST (U/L)                        | 35.04 ± 14.58            | 33.81 ± 16.19               | 35.50 ± 17.84   | 0.02    |
| ALP (U/L)                        | 76.06 ± 21.71            | 78.67 ± 29.75               | 77.31 ± 26.07   | 0.736   |
| GGT (U/L)                        | 39.13 ± 43.35            | 42.76 ± 45.72               | 41.50 ± 47.42   | 0.622   |
| Albumin (g/L)                    | 44.45 ± 5.32             | 44.60 ± 4.98                | 44.48 ± 5.26    | 0.039   |
| TBil (μmol/L)                    | 15.65 ± 16.36            | 19.00 ± 29.98               | 16.94 ± 22.78   | 0.037   |
| PT (S)                           | 12.74 ± 1.25             | 12.36 ± 1.72                | 12.56 ± 1.49    | 0.001   |
| HBsAg (log_{10}IU/ML)            | 3.56 ± 0.94              | 3.57 ± 0.81                 | 3.56 ± 0.88     | 0.583   |
| Collagen IV (Pg/ML)              | 936.82 ± 610.24          | 866.57 ± 472.39             | 869.97 ± 540.96 | 0.401   |
| Hyaluronic (μg/L)                | 124.20 ± 73.76           | 107.49 ± 68.30              | 115.26 ± 71.14  | 0.001   |
| Laminin (μg/L)                   | 94.56 ± 206.58           | 75.71 ± 145.84              | 84.24 ± 177.79  | 0.661   |
| PIIINP (μg/L)                    | 3.59 ± 5.31              | 3.75 ± 4.86                 | 3.65 ± 5.04     | 0.442   |
| HBsAg (positive, %)              | 136 (61.0%)              | 131 (55.3%)                 | 267 (58.7%)     | 0.221   |
| HBV DNA (log_{10}IU/ML)          | 6.14 ± 1.93              | 5.69 ± 2.08                 | 5.89 ± 2.03     | 0.034   |
| Fibrosis stages (n, %)           |                          |                             |                 | 0.835   |
| F0                               | 9 (4%)                   | 11 (4.6)                    | 20 (4.3%)       |         |
| F1                               | 70 (31.4%)               | 66 (27.8)                   | 136 (29.6%)     |         |
| F2                               | 62 (27.8%)               | 73 (30.8%)                  | 135 (29.3%)     |         |
| F3                               | 40 (17.9%)               | 45 (19%)                    | 85 (18.5%)      |         |
| F4                               | 34 (15.2%)               | 34 (14.3%)                  | 68 (14.8%)      |         |
| F5–6                             | 8 (3.6%)                 | 8 (3.4%)                    | 16 (3.5)        |         |

BMI: body mass index; ALT: alanine transaminase; AST: aspartate transaminase; ALP: alkaline phosphatase; GGT: gamma-glutamyltransferase; PT: prothrombin time; HBV: hepatitis B virus; HBsAg: HBV surface antigen; LN: laminin; PIIINP: Procollagen III N-terminal Peptide.
parameters which showed significantly higher or lower in patients with significant/severe fibrosis (F ≥ 3) were included in multivariate analysis (Table 2). It indicated that serum Angptl2 concentration (\(p = 0.007\)), PLT (\(p = 0.040\)), AST (\(p = 0.005\)), hyaluronic (\(p = 0.002\)), and LN (\(p = 0.007\)) were independently associated with Ishak fibrosis score ≥ 3.

Based on the variables above, we developed an ACI by binary logistic regression.

\[
G_x = -1.774 + 0.027 \times \text{AST} - 0.01 \times \text{PLT} + 0.144 \times \text{Angptl2} + 0.004 \times \text{Laminin} + 0.009 \times \text{Hyaluronic}
\]

\[
\text{ACI} = \exp(G_x)/(1 + \exp(G_x)).
\]

ACI was compared with APRI, FIB-4, Forn’s index and Hui model for predicting significant fibrosis in training cohort

To assess the efficiency of models in predicting significant fibrosis, ROC curves were created (Fig. 2). In the training cohort (223 patients), the AUC of ACI for distinguishing patients who showed significant fibrosis (F ≥ 3) from patients who have no significant fibrosis (F0–2) was 0.835 (95% CI: 0.781, 0.889). Using a cutoff value of ≥ 0.2, ≥ 0.3, ≥ 0.5, patients who need immediate anti-HBV therapy could be correctly identified with a sensitivity of 93.8%, 85.2%, 55.6%, a specificity of 44.0%, 67.2%, 85.8%, a of 50.3%, 61.1%, 70.3%, and a NPV of 92.2%, 88.2%, 76.2% respectively.

Compared to the existing non-invasive assessments, ACI was superior to APRI (AUC = 0.776 (95% CI: 0.713, 0.840)) (\(P = 0.049, Z = 1.962\)), FIB-4 (AUC = 0.750 (95% CI: 0.684, 0.816)) (\(P = 0.010, Z = 2.571\)), Hui model (AUC = 0.756 (95% CI: 0.685, 0.827)) (\(P = 0.028, Z = 2.191\)) and had a better trend than Forn’s index (AUC = 0.796 (95% CI: 0.732, 0.860)) (\(P = 0.083, Z = 1.732\)) for predicting significant fibrosis (F ≥ 3) in the training group (Fig. 2 A).

Assessment of noninvasive predictive models in the validation cohort

Serum Angptl2 concentration showed closely association with Ishak fibrosis scores for patients in training group (Additional file 1: Fig. S1). Diagnostic value of ACI was further assessed together with APRI, FIB-4, Forn’s index, Hui model for predicting significant fibrosis in the training cohort by Univariate and Multivariate Analyses

| Parameters          | Univariate analysis | Multivariate analysis |
|---------------------|---------------------|-----------------------|
|                     | F0–2 (n = 141)      | F ≥ 3 (n = 82)        | P        | Exp (B) (95%CI) | P        |
| Gender (Male, %)    | 113 (80.1%)         | 57 (69.5%)            | 0.076   | 1.219 (0.637, 2.332) | 0.550   |
| Age (≥35 year, %)   | 51 (36.2%)          | 47 (57.3%)            | 0.03    | 1.029 (0.988, 1.072) | 0.165   |
| BMI (≥24 kg/m2, %)  | 51 (36.2%)          | 31 (37.8%)            | 0.886   |                     |         |
| Platelet count (× 109/L) | 190.68 ± 53.07   | 142.49 ± 49.17       | <0.001  | 0.990 (0.985, 0.995) | 0.001   |
| ALT (IU/L)          | 42.99 ± 17.28       | 46.18 ± 16.68        | 0.159   | 0.987 (0.969, 1.005) | 0.158   |
| AST (IU/L)          | 31.46 ± 10.24       | 41.34 ± 18.53        | <0.001  | 1.027 (1.008, 1.047) | 0.005   |
| ALP (IU/L)          | 72.03 ± 19.22       | 83.55 ± 24.05        | 0.001   | 1.006 (0.994, 1.017) | 0.339   |
| GGT (IU/L)          | 27.70 ± 21.92       | 59.06 ± 61.50        | <0.001  | 1.005 (0.996, 1.013) | 0.28    |
| Albumin (g/L)       | 45.04 ± 4.97        | 43.27 ± 5.78         | 0.001   | 1.027 (0.973, 1.084) | 0.334   |
| TBil (μmol/L)       | 15.41 ± 19.93       | 16.01 ± 8.11         | 0.182   |                     |         |
| PT (s)              | 12.54 ± 1.14        | 13.10 ± 1.38         | <0.001  | 1.067 (0.879, 1.296) | 0.509   |
| HBeAg (positive, %) | 89 (63.1%)          | 47 (57.3%)            | 0.397   |                     |         |
| HBV DNA (log10IU/ML)| 6.43 ± 1.97         | 5.64 ± 1.77          | <0.001  | 0.782 (0.603, 1.013) | 0.063   |
| Collagen IV (Pg/ML) | 774.30 ± 302.67     | 1175.98 ± 887.97     | <0.001  | 1.000 (0.999, 1.002) | 0.472   |
| Hyaluronic (μg/L)   | 97.83 ± 37.96       | 155.78 ± 86.27       | <0.001  | 1.010 (1.004, 1.016) | 0.002   |
| Laminin (μg/L)      | 32.36 ± 50.72       | 196.10 ± 312.13      | <0.001  | 1.004 (1.001, 1.006) | 0.007   |
| PIIIINP (μg/L)      | 2.97 ± 5.79         | 4.85 ± 4.98          | <0.001  | 0.968 (0.908, 1.103) | 0.312   |
| HBV DNA/HBeAg (n, %)| 6.43 ± 1.97         | 5.64 ± 1.77          | <0.001  | 0.782 (0.603, 1.013) | 0.063   |
| Angptl2 (ng/ml)     | 4.54 ± 1.96         | 6.07 ± 3.23          | 0.008   | 1.152 (1.039, 1.278) | 0.007   |
and Hui model (Fig. 3). For predicting significant fibrosis in validation group, the AUROCs were 0.795 (95% CI: 0.730, 0.851) for ACI, 0.715 (95% CI: 0.647, 0.783) for APRI, 0.730 (95% CI: 0.661, 0.799) for FIB-4, 0.735 (95% CI: 0.658, 0.811) for Forns’ index, and 0.719 (95% CI: 0.646, 0.791) for Hui model (Fig. 3A). For patients with normal ALT, the AUC of ACI for predicting significant fibrosis, the indication of urgent anti-HBV therapy was 0.810 (95% CI: 0.727, 0.893), and the AUCs of APRI, FIB-4, Forns’ index and Hui model were 0.766 (95% CI: 0.675, 0.858), 0.717 (95% CI: 0.608, 0.826), 0.732 (95% CI: 0.607, 0.856), 0.721 (95% CI: 0.610, 0.832), respectively (Fig. 3B).

In total 460 patients, predictive accuracy of the models for diagnosing significant fibrosis were calculated, data was shown in Table 3.

**Discussion**

The indications for antiviral treatment of hepatitis B were at a long time generally based mainly on the combination of three criteria: serum HBV DNA levels, serum ALT levels and severity of liver disease. According to the treatment criteria of the APASL guideline [4], this 460 patients with ALT <2 × ULN should monitor ALT level every 3 months, biopsy was considered if ALT was persistently elevated, noninvasive tests suggested evidence of significant fibrosis, age > 35 years or family h/o HCC or cirrhosis. In the guideline, although the additional factors were taken into account, the antiviral treatment decision for patients with ALT <2 × ULN still depended on hepatic histology, which is a significantly invasive process.

To date, many publications have demonstrated the growing interest in non-invasive biomarkers and indexes to overcome the limitations of liver biopsy. Individual markers, such as hyaluronate [23], type IV collagen [24], MMPs [25], and CD163 [26, 27], as well as indexes, such as APRI, AAR, FIB-4, Forns’ index and Hui model, have been the most extensively studied. However, the majority of studies investigating non-invasive markers have focused only patients with ALT ≥2 × ULN.

Although ALT levels reflect liver inflammation to some degree, Recent data has increasingly shown that patients with normal or mildly elevated serum ALT levels are not guaranteed to be free from liver damage and liver-related mortality [28]. Twenty eight to thirty seven percent of patients with normal ALT levels were reported to exhibit histologically advanced fibrosis [29–31]. However, few existed serum markers were available that exhibited efficacy for diagnosing significant fibrosis or that aid in treatment decision making in clinical practice, for patients

---

**Fig. 2** Receiver operating characteristics (ROC) curves of the Angptl2 combined index (ACI), APRI, FIB-4, Forns’ index to distinguish patients with and without significant fibrosis in the Training cohort. (a) Area under the ROC curves (AUC) of above models in the training set. (b) AUC for above models in patients with Normal ALT in the training set.

**Fig. 3** Receiver-operating characteristic curve (ROC) curves of the ACI, APRI, FIB-4, Forns’ index to distinguish patients with and without significant fibrosis in the Validation cohort. (a) AUC of above models in the validation set. (b) AUC of above models in patients with normal ALT in validation set.
with normal or minimally elevated ALT. In our study, 36.8% of 460 patients who needed biopsies to determine treatment decisions had significant fibrosis. Therefore, non-invasive markers for predicting fibrosis in patients with normal ALT are needed.

This study demonstrated that Angptl2 was significantly associated with fibrosis in patients with normal and minimally elevated ALT. Furthermore, multivariate analysis identified Angptl2 concentration as an independent predictive factor, together with PLT, LN, AST and hyaluronic acid, and developed a model, ACI. To investigate the efficiency of ACI, we performed further ROC analyses and found it superior to the other 4 existing fibrosis models (APRI, FIB-4, Forns’ index and Hui model). Additionally, validation cohort revealed its robustness and reliability. There was also some problem about standard detection method of angptl2. The circulatory level of Angptl2 in healthy people of different articles changed [13–15], it would be due to measurement by different commercial kit. In this study, the normal level of ANGPTL2 in 30 healthy people was 3.92 ± 1.53 (ng/ml). In the further, the standard kit for testing ANGPTL2 was needed for clinic application.

Normal Angptl2 signaling functions in angiogenesis and tissue repair, whereas excess Angptl2 signaling leads to chronic inflammation and subsequent pathological irreversible tissue remodeling [8]. It was reported that expression of Angptl2 induced by mechanical stress in LF fibroblasts promotes ligamentum flavum (LF) tissue degeneration by activation of TGF-β1/Smad signaling, which resulted in LF hypertrophy in patients with lumbar spinal canal stenosis [32]. Additionally, high levels of Angptl2 protein positively

### Table 3 Predictive accuracy of ACI and other index for diagnosing significant fibrosis in total patients

| Index          | Patients | AUC (95% CI) | Cut-off | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | LR     |
|----------------|----------|-------------|---------|-----------------|-----------------|---------|---------|--------|
| ACI            | ALT < 2 × ULN (n = 460) | 0.813 (95% CI: 0.772, 0.854) | ≥ 0.2  | 88.0            | 50.9            | 51.3    | 90.8    | 1.6    |
|                | Normal ALT (n = 196)      | 0.824 (95% CI: 0.763, 0.884) | ≥ 0.2  | 81.8            | 63.7            | 54.0    | 87.5    | 2.25   |
| APRI           | ALT < 2 × ULN (n = 460) | 0.742 (95% CI: 0.695, 0.789) | ≥ 0.5  | 70.0            | 63.6            | 53.9    | 78.8    | 2.07   |
|                | Normal ALT (n = 196)      | 0.780 (95% CI: 0.710, 0.849) | ≥ 0.5  | 55.2            | 85.8            | 58.9    | 78.3    | 3.90   |
| FIB-4          | ALT < 2 × ULN (n = 460) | 0.741 (95% CI: 0.693, 0.788) | ≥ 1.0  | 26.4            | 94.4            | 73.8    | 68.9    | 4.71   |
|                | Normal ALT (n = 196)      | 0.763 (95% CI: 0.689, 0.830) | ≥ 1.0  | 16.4            | 98.4            | 84.6    | 69.1    | 10.43  |
| Forns’ index   | ALT < 2 × ULN (n = 460) | 0.766 (95% CI: 0.717, 0.816) | ≥ 2.6  | 90.1            | 37.5            | 44.9    | 86.4    | 1.44   |
|                | Normal ALT (n = 196)      | 0.762 (95% CI: 0.689, 0.847) | ≥ 2.6  | 54.6            | 83.5            | 64.7    | 75.8    | 3.3    |
| Hui Model      | ALT < 2 × ULN (n = 460) | 0.736 (95% CI: 0.686, 0.787) | ≥ 2.05 | 60.1            | 74.4            | 58.1    | 76.5    | 2.55   |
|                | Normal ALT (n = 196)      | 0.745 (95% CI: 0.664, 0.825) | ≥ 2.05 | 38.5            | 90.9            | 71.3    | 71.7    | 4.25   |

Deng et al. BMC Infectious Diseases (2017) 17:650
was correlated with histological grade, and liver cirrhosis HCC patients [33]. In this study, Angptl2 exhibited association with liver fibrosis in hepatitis B patients. As discussed above, this may suggests that Angptl2 promote liver fibrogenesis through TGF-β1/Smad signaling, the most potent factor in stimulating collagen gene transcription. The mechanistic studies will be required to clarify the issue.

The current study has limitations that are presented below. First, it is a cross-sectional study. Although a longitudinal study is more powerful in an observational study, most study refer to noninvasive assessment of liver fibrosis are cross-sectional and our multi-center data could be the offset. Second, in this study, normal and minimally elevated ALT is defined within one test and without monitoring it every 3 months. However ALT is just the marker for assessing liver inflammation, but not a marker for diagnosing hepatic fibrosis. Additionally, ALT monitoring always takes time in clinical practice, noninvasive marker superior to ALT to diagnose fibrosis stages could benefit to treatment decision making. The third limitation of our study is clinical research and no mechanism exploration. The basic research of the relationship between Angptl2 and liver fibrosis is currently in progress. Of course, missing imaging examination is also the drawback of this study. The last limitation was that the Angptl2 levels in patients with F3–6 were overlapped with those in patients with F0–2, suggesting the difficulties to set up a cut-off level to estimate the fibrosis stages in chronic hepatitis B patients. So, we developed the ACI model based on Angptl2 together with conventional markers to avoid this problem.

Conclusion
Although serum Angptl2 concentration needs more extensive validation in the future, the results from this multicenter, prospective study was sufficient to suggest serum Angptl2 concentration as a potentially novel biomarker for predicting the severity of liver injury. In addition, the angptl2 combined index ACI did better in diagnosing significant fibrosis in hepatitis B patients, compared with APRI, Hui model, FIB-4, Forn’s index.

Additional file

Additional file 1: Fig. S1. Boxplot of the serum Angptl2 concentrations in relation to fibrosis score in Validation cohort (A) and patients with normal ALT (B). The above and below lines indicate the SD. The middle line represents the medians. *** p < 0.001, ** p < 0.01, and * p < 0.05. For all patients in the validation cohort, p < 0.001. For patients with normal ALT in validation cohort, p = 0.002. (TIFF 75 kb)

Abbreviations
AASLD: American Association for the Study of Liver Diseases; ALT: Alanine aminotransferase; Angptl2: Angiopoietin-like protein 2; APASL: the Asian Pacific Association for the Study of Liver; AST: Aspartate aminotransferase; AUC: Area under the curve; BMI: Body mass index; ECM: Extracellular matrix; GGT: Gamma-glutamyltransferase; HAI: Histological activity index; HBsAg: HBV surface antigen; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; IN: Laminin; MAPK: Mitogen-activated protein kinase; MMP: Matrix metalloproteinase; NPV: Negative predictive value; PIIINP: Procollagen type III N-terminal peptide; PPV: Positive predictive value; PT: Prothrombin time; ROC: Receiver-operating characteristic curves; SD: Standard deviation; Tbil: Total bilirubin; ULN: upper limit of normal

Acknowledgements
Additional group members of China HepB Related Fibrosis Assessment Research Group: An-Lin Ma, from departments of Infectious Disease, China-Japan Friendship Hospital, Beijing; Shi-Bin Xie, from departments of Infectious Disease, The Third Affiliated Hospital Sun Yat-Sen University, Guangzhou, Guangdong; Xu-Qing Zhang, from department of Infectious Diseases, South West Hospital affiliated to Third Military Medical University, Chongqing; Da-Zhi Zhang, from department of Infectious Diseases, Second Affiliated Hospital Of Chongqing Medical University, Chongqing; Qing Xie, from department of Infectious Diseases, Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai; Guo Zhang, from department of Infectious Diseases, The People’s Hospital Of Guang Xi Zhuang Autonomous Region, Nanning, Guangxi; Jia Shang, from department of Infectious Diseases, The People’s Hospital Of He Nan province, Zheng zhou, Henan; Jun Chen, from department of Infectious Diseases, Di Tan Hospital affiliated to Capital Medical University, Beijing; Wei-Feng Zhao, MM, from department of Infectious Diseases, Xinxing Medical University Third Hospital, Xinxing Hospital, Henan; Zhi-Qiang Zhou, from department of Infectious Diseases, Yantai City Hospital for Infectious Disease, Yantai, Shandong; Ying-Xiu Liu, from department of Infectious Diseases, Shenzhen Third People’s hospital of, Shenzhen; Zhan-Qin Zhang, from department of Infectious Diseases,Public Health Clinical Center Affiliated to Fudan University, Shanghai; Xun Peng, Xie-Wen Sun, from department of Infectious Diseases, Third Hospital Of Qin Huang Dao, Qin Huang Dao, Hebei; Ming-Xiang Zhang, from department of Infectious Diseases, Shenyang Sixth People’s Hospital, Shenyang, Liaoning; Fu-Dong Lv, from department of pathology, You An Hospital affiliated to Capital Medical University, Beijing; Jun Li, from department of Infectious Diseases, Jiang Su Province Hospital, Nanjing, Jiangsu; Wan-Li Sun, from department of Infectious Diseases, Dalian Sixth People’s Hospital, Dalian, Shandong; Lang Bai, from department of Infectious Diseases, West China School of Medicine/West China Hospital Sichuan University, Chengdu, Sichuan; Li-Ming Chen, from department of Infectious Diseases, Dan Li, from department of Infectious Diseases, Jiang Su Province Hospital, Nanjing, Jiangsu; Yan Li, from department of Infectious Diseases, Dalian, Shandong; Qiu Zhi, from department of Infectious Diseases, Dan Liu, Hong-Li Xi, Yi-Hang Zhou, Min Yu, from department of Infectious Diseases, Center for Liver Disease, Peking University First Hospital, Beijing. We thank Professor Xin Xu (Nanjang Medical University) for his guidance with the statistics.

Funding
This study was supported by China Mega-Project for Infectious Diseases (grant number 2013ZX10002005, 2012ZX10002006), Project of Beijing science and technology committee (grant number D121100003912002) and National Key Clinical Program of the Ministry of Health.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author’s contributions
YD: completing experimental detection, analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; statistical analysis. HZ: study concept and design; acquisition of data; analysis and interpretation of data; critical revision of the manuscript for important intellectual content; technical and material support. JZ, LY: acquisition of data; analysis and interpretation of data; GW: study concept and design; analysis and interpretation of data; critical revision of the manuscript for important intellectual content; obtained funding; study supervision. YD, HZ, JZ, LY, and GW read, commented and approved the final manuscript.
Ethics approval and consent to participate

All patients provided written informed consent for the scientific use of their data and samples, and the study was approved by the Ethical Committee of Peking University First Hospital.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1. Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, No. 8, Xishiku Street, Xicheng District, Beijing 100034, China.
2. The Department of Dermatology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
3. The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Zhejiang, Hangzhou, China.
4. The coordination innovation center

Received: 17 April 2017 Accepted: 12 September 2017

Published online: 29 September 2017

References

1. Schweitzer A, Horn J, Moklajczyk RT, Krause G, Ott J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(9996):46–55.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to liver cancer worldwide. J Hepatol. 2006;45:529–38.
3. Lian J, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27:6550–7.
4. Sarin SK, Kumar M, Lai GK, Abbas Z, Chou HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B. A 2015 update. Hepatol Int. 2016;10:1–98.
5. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol. 2003;39:239–44.
6. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in patients with chronic hepatitis C. J Hepatol. 2007;46:32–6.
7. Hui AY, Chan HL, Wong WW, Liew CT, Chim AM, Chan FK, et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol. 2005;100:616–23.
8. Valls-Pichard A, Mallet V, Dalpols B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection comparison with liver biopsy and fibrotic. Hepatology. 2007;46:32–6.
9. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36:896–92.
10. Ishak K, Baptista A, Bianchi L, Callée F, De Groot E, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–9.
11. Walsh KM, Fletcher A, MacSweeney RN, Morris AJ. Basement membrane peptides as markers of liver disease in chronic hepatitis C. J Gastroenterol Hepatol. 2000;15:32–30.
12. Murawaki Y, Koda M, Okamoto K, Mimura K, Kawasaki H. Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. J Gastroenterol Hepatol. 2001;16:777–81.
13. Murawaki Y, Ikuta Y, Idoye B, Kawasaki H. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. J Gastroenterol Hepatol. 1999;14:138–45.
14. Kazankov K, Barrena F, Moller HJ, Bibby BM, Vilstrup H, George J, et al. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology. 2014;59:21–30.
15. Grenbaek H, Sandahl TD, Montensen C, Vilstrup H, Moller HJ, Moller S. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. Aliment Pharmacol Ther. 2012;36:173–80.
16. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Inactivation of the American Association for the study of liver disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47:1363–70.
17. Kumar M, Sarin SK, Hitsar S, Pande C, Saluja P, Sharma BC, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterol. 2008;31:1367–84.
18. Lai M, Hyatt BJ, Naseri I, Curry M, Adhikai NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47:760–7.
19. Tsang PS, Tin HH, Garcia RT, Phan JT, Ha NB, Nguyen H, et al. Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. Clin Gastroenterol Hepatol. 2008;6:569–74.
20. Nakamura T, Okada T, Endo M, Kodamatsu T, Taniwaki T, Sei A, et al. Angiopoietin-like protein 2 induced by mechanical stress accelerates degeneration and hypertrophy of the Ligamentum Flavum in lumbar Spinal Canal Stenosis. PLoS One. 2014;10(7):e98542.
21. Gao L, Ge C, Fang T, Zhao F, Chen T, Yao M, et al. ANGPTL2 promotes tumor metastasis in Hepatocellular carcinoma. J Gastroenterol Hepatol. 2015;30:396–404.